immatics biotechnologies GmbH (IMTXW)

US — Healthcare Sector
Peers: MDG1.HM  VSC.MU  4A3.BE  1VT.BE  MOR.F  ATNFW 

Automate Your Wheel Strategy on IMTXW

With Tiblio's Option Bot, you can configure your own wheel strategy including IMTXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMTXW
  • Rev/Share 1.1859
  • Book/Share 4.4147
  • PB 1.2083
  • Debt/Equity 0.0343
  • CurrentRatio 10.2844
  • ROIC -0.1247

 

  • MktCap 648395104.5
  • FreeCF/Share -1.3992
  • PFCF -3.8125
  • PE -30.0405
  • Debt/Assets 0.0287
  • DivYield 0
  • ROE -0.0459

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About immatics biotechnologies GmbH (IMTXW)

  • IPO Date 2020-07-02
  • Website https://www.immatics.com
  • Industry Biotechnology
  • CEO Harpreet Singh
  • Employees 554
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.